SNPMiner Trials (Home Page)
Report for Mutation R230C
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Effect of the R230C Variant of the ATP-binding Cassette Transporter A1 (ABCA1) Gene on the Response to Treatment With Glibenclamide in Patients With Type 2 Diabetes Mellitus
The objective of the study is to know if the R230C and C230C variants of the ATP-binding cassette transporter A1 (ABCA1) gene are associated with a smaller glucose lowering effect compared to the wild type allele (R230R) in patients with type 2 diabetes.
NCT01456650 Type 2 Diabetes Drug: Glyburide MeSH:Diabetes Mellitus, Type 2
HPO:Type II diabetes mellitus
Effect of the R230C Variant of the ATP-binding Cassette Transporter A1 (ABCA1) Gene on the Response to Treatment With Glibenclamide in Patients With Type 2 Diabetes Mellitus. --- R230C ---
R230C and C230C Variants of ABCA1 and Glyburide Response The objective of the study is to know if the R230C and C230C variants of the ATP-binding cassette transporter A1 (ABCA1) gene are associated with a smaller glucose lowering effect compared to the wild type allele (R230R) in patients with type 2 diabetes. --- R230C ---
R230C and C230C Variants of ABCA1 and Glyburide Response The objective of the study is to know if the R230C and C230C variants of the ATP-binding cassette transporter A1 (ABCA1) gene are associated with a smaller glucose lowering effect compared to the wild type allele (R230R) in patients with type 2 diabetes. --- R230C --- --- R230C ---
In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following continuous variables: - Fasting glucose - Percentage reduction - Hemoglobin A1c, - Cholesterol, triglycerides, HDL cholesterol, LDL cholesterol - Weight 2. In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following binomial variables: - Number of cases that reach fasting plasma glucose lower than 110 mg/dl - Number of cases that reach an HbA1c less than 7% --- R230C ---
In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following continuous variables: - Fasting glucose - Percentage reduction - Hemoglobin A1c, - Cholesterol, triglycerides, HDL cholesterol, LDL cholesterol - Weight 2. In patients with type 2 diabetes stratified by the existence of the risk alleles (R230C/C230C) or the wild variant (R230R) of ABC-A1, compare the changes resulting from the treatment with glibenclamide on following binomial variables: - Number of cases that reach fasting plasma glucose lower than 110 mg/dl - Number of cases that reach an HbA1c less than 7% --- R230C --- --- R230C ---
Primary Outcomes
Description: The effects of the alleles under study on the glucose lowering effect of glyburide will be assessed in 20 week study. Diet and exercise will be controlled per protocol
Measure: Change in plasma fasting glucose Time: 20 weeks